Blog - Page 754 of 5695 - QualityStocks

MondayMar 13, 2023 2:30 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) On Track to Advance Innovative Products

HeartBeam (NASDAQ: BEAT) is a cardiac technology company dedicated to finding effective ways to detect heart attacks earlier than ever before. “The company has two patented products in development: HeartBeam AIMI(TM), software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately; and HeartBeam AIMIGo(TM), the first and only credit-card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart attack detection,” a recent article reads. “Although HeartBeam AIMI and HeartBeam AIMIGo have not yet been cleared by the U.S.…

MondayMar 13, 2023 12:21 pm

QualityStocksNewsBreaks – Iconic Brands Inc. (ICNB) Announces Listing on OTCQB Market

Iconic Brands (OTCQB: ICNB), a leader in the development, design and delivery of alcohol and non-alcohol beverages, today announced that it regained compliance with OTC Markets and is listed on the OTCQB under the ticker symbol ICNB. “We are happy to announce that we have regained compliance with OTCQB Markets,” said Richard DeCicco, chairman of the board and president of Iconic. “The complete integration of our sustainable packaging business is a significant achievement for our company, and we are proud to demonstrate our commitment to our stockholders and investors in regaining our listing status with the OTC Markets. 2023 should…

MondayMar 13, 2023 11:51 am

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Peer-Reviewed Study Results Published

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has announced that results of its study have been published in the “International Journal of Molecular Sciences.” The study was designed to evaluate the anti-inflammatory effects of rare cannabinoids and their potential application for the treatment of skin conditions, including atopic dermatitis, psoriasis, pruritus and acne. The study is titled “Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signalling Pathway.” According to the announcement, study results demonstrate the therapeutic potential of rare cannabinoids in the…

MondayMar 13, 2023 11:34 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces It Has No Exposure to Silicon Valley Bank Issues

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that it is aware that the Federal Deposit Insurance Corp. has taken control of Silicon Valley Bank (“SVB”) due to liquidity concerns. CNS Pharmaceuticals does not hold any deposits or investments at SVB. To view the full press release, visit https://ibn.fm/1EM7p About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the…

MondayMar 13, 2023 11:05 am

QualityStocksNewsBreaks – CISO Global Inc. (NASDAQ: CISO) Announces Participation in Upcoming Roth Conference

CISO Global Inc. (NASDAQ: CISO), an industry leader as a managed cybersecurity and compliance provider, will be participating in the 35th annual Roth Conference. The conference, which is slated for March 12–14, 2023, will be held in Dana Point, California, and will feature numerous one-on-one and small-group meetings, as well as analyst-selected fireside chats and thematic industry panels. In addition, leaders from an estimated 400 private and public companies will give presentations. Those companies will come from an array of different industries, including business services, health and wellness, oil and gas, metals and mining, technology, media and agtech, and sustainability.…

MondayMar 13, 2023 10:30 am

Silo Pharma Inc. (NASDAQ: SILO) Set to Benefit as Study Supports the Efficacy of Psychedelics in Treating ‘Drug-Resistant’ Depression

A recent medical study found that psychedelic drugs showed promise as a treatment alternative for hard-to-treat depression Psychedelics were found to activate a greater number of serotonin 2A receptors then traditional antidepressant drugs, largely because of their ability to penetrated through cells’ fatty outer membranes The study reinforces the potential use of psychedelic drugs, and psilocybin in particular, as a treatment methodology for a variety of mental health related conditions Silo Pharma, a developmental stage biopharmaceutical company has long focused around merging traditional therapeutics with psychedelic research In a study carried out between 2013 to 2016, researchers found that 8.1%…

MondayMar 13, 2023 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leverages Top-Tier Leadership and GMP Facility to Advance Rapid Development of New Therapeutic and Prophylactic Technologies for Multiple Diseases and Disorders

BiondVax is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, primarily for the treatment of infectious and autoimmune diseases The company is led by CEO Amir Reichman, with over 20 years of international experience as a biopharma expert Amir took company reins in 2021 and pivoted the mission and vision including diversifying risks With new focus and opportunity, BiondVax now developing an innovative alpaca-derived nanosized antibody (“NanoAb”) pipeline BiondVax is aggressively advancing new NanoAb therapeutic and prophylactic technologies owing to exclusive collaborations, previous pharma development experience and a state-of-the-art GMP manufacturing facility Leveraging top-tier pharmaceutical industry…

MondayMar 13, 2023 9:00 am

McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) subsidiary McEwen Copper adds $30 Million Boost from Nuton LLC to recent Stellantis investment of $155 Million, Plans for subsidiary IPO

McEwen Mining subsidiary McEwen Copper has been gaining increased financial support as it develops a major copper mine opportunity in Argentina described as one of the 10 largest undeveloped deposits in the world Mining giant Rio Tinto’s venture Nuton LLC has boosted last year’s $25 million investment into McEwen Copper with a new $30 million addition, all on top of the recent Stellantis investment of approximately $155 million The project in Argentina’s San Juan province benefits from a mining-friendly government and population The demand for copper is expected to continue to grow as a result of its importance to green…

FridayMar 10, 2023 3:45 pm

QualityStocksNewsBreaks – EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) Ideally Poised as Increased RNG Use Expected to Catalyze Growth

EverGen (TSX.V: EVGN) (OTCQX: EVGIF), a leading Canadian renewable energy company and Canada’s renewable natural gas (“RNG”) infrastructure platform, aims to advance Canada’s RNG infrastructure by building a network spanning 20+ facilities within five years. “The company acquires, develops, builds, owns, and operates a portfolio of RNG waste-to-energy and related infrastructure projects on the west coast in British Columbia, and toward the east with facilities in Alberta and Ontario… EverGen owns and operates five RNG and/or organic processing facilities across Canada,” a recent article reads. “RNG is considered environmentally sustainable because it is derived from sources that otherwise would release…

FridayMar 10, 2023 1:18 pm

QualityStocksNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Bringing Hope for Alzheimer’s Treatment

India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study. This is groundbreaking work that established its commitment as a pioneer in the treatment of Alzheimer’s disease, given there are no currently FDA-approved drugs to treat Alzheimer’s patients. “The company is developing its proprietary treatment, IGC-AD1, hoping to provide relief to the 55 million people worldwide struggling with agitation in dementia that results from Alzheimer’s. IGC is focused on revolutionizing the treatment of Alzheimer’s with its game-changing drug candidate. In phase 1 studies,…

Site Search

Company Search